IMUX

SEC source: 0001280776-18-000095 · wf-form4_153791811594828.xml · nonDerivative · entry 1

Halperin Errol R. · CIK 0001591095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001280776-18-000093 · wf-form4_153783147353536.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-18-000091 · wf-form4_153756112908197.xml · nonDerivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 3

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

F7 · shares: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4.

F9 · ownership.nature: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4.

SEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,044,777

F4 · shares: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4.

F6 · ownership.nature: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest.

SEC source: 0001280776-18-000088 · wf-form4_153723394976637.xml · nonDerivative · entry 2

Hasnain Faheem · CIK 0001352620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

SEC source: 0001280776-18-000088 · wf-form4_153723394976637.xml · nonDerivative · entry 1

Hasnain Faheem · CIK 0001352620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,743

SEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,492,277

F1 · shares: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-18-000087 · wf-form4_153723383634954.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,119

SEC source: 0001280776-18-000085 · wf-form4_153695571919596.xml · nonDerivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · ownership.nature: Shares held by Cheryl L. Cohen Trust U/A 04/01/05 Cheryl L. Cohen Trustee.

SEC source: 0001280776-18-000075 · wf-form4_153065083078370.xml · derivative · entry 1

Stern Aron · CIK 0001591106 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-06-30

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000069 · wf-form4_152875934073633.xml · derivative · entry 1

MURAWSKI RICHARD M · CIK 0001022850 · Vice President, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000073 · wf-form4_152875942911815.xml · derivative · entry 1

Nash Duane · CIK 0001591098 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000072 · wf-form4_152875940863326.xml · derivative · entry 1

Henry Andrew · CIK 0001591104 · VP, Clinical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000071 · wf-form4_152875938337968.xml · derivative · entry 1

Ashley Robert A. · CIK 0001591017 · Chief Technical Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000070 · wf-form4_152875936106799.xml · derivative · entry 1

Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000068 · wf-form4_152875931831922.xml · derivative · entry 1

DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2028-06-08

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 9, 2018, such that all of the shares of common stock subject to the option are vested by June 9, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-18-000040 · wf-form4_152727884006375.xml · derivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000045 · wf-form4_152727896677922.xml · derivative · entry 1

Hasnain Faheem · CIK 0001352620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,353

Underlying: Common Stock · 41,353 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000046 · wf-form4_152727898790036.xml · derivative · entry 1

Halperin Errol R. · CIK 0001591095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000043 · wf-form4_152727894752915.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000042 · wf-form4_152727892665112.xml · derivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000041 · wf-form4_152727885948403.xml · derivative · entry 1

Millis J. Michael · CIK 0001591498 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000039 · wf-form4_152727882222142.xml · derivative · entry 1

SEARS LOWELL · CIK 0001189160 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000038 · wf-form4_152727880596273.xml · derivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

Underlying: Common Stock · 29,538 shares

Expires 2028-05-22

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders.

SEC source: 0001280776-18-000004 · wf-form4_151511784041634.xml · derivative · entry 1

Cox Russell J. · CIK 0001512984 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,588,832

Underlying: Common Stock · 1,588,832 shares

Expires 2028-01-02

F1 · derivative.exercise_date: Twenty five (25%) of the shares of common stock subject to the option shall vest one year from January 3, 2018, and thereafter, one forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly, such that all of the shares of common stock subject to the option are vested by January 3, 2022, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended & Restated 2017 Inducement Equity Incentive Plan (the "Plan)) through each vesting date; provided, that, the unvested portion of the option, if any, that would vest during the 12-month period following his termination date had he remained employed by the Issuer through such date shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-17-000104 · wf-form4_151329524009150.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,382,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.225 to $5.70. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000104 · wf-form4_151329524009150.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,332,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.00 to $5.85. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 3

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,282,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,232,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.775 to $5.05. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,182,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.475 to $5.00. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 3

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,132,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.075 to $4.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000092 · wf-form4_150550674325248.xml · nonDerivative · entry 1

Hasnain Faheem · CIK 0001352620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,943

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.925 to $4.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,102,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.20. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000088 · wf-form4_150542014038755.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,119

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.95 to $4.1347. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,052,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.625 to $3.90. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000086 · wf-form4_150524726233137.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,002,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.65. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000084 · wf-form4_150472861787568.xml · derivative · entry 1

Hasnain Faheem · CIK 0001352620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,222

Underlying: Common Stock · 15,222 shares

Expires 2027-09-04

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from September 5, 2017 or the day prior to the Company's 2018 annual meeting of stockholders.

SEC source: 0001280776-17-000072 · wf-form4_149747478861937.xml · nonDerivative · entry 2

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,952,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.025 to $3.25. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000075 · wf-form4_149755857797011.xml · nonDerivative · entry 2

DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,885

SEC source: 0001280776-17-000075 · wf-form4_149755857797011.xml · nonDerivative · entry 1

DUNN JOHN MICHAEL · CIK 0001238648 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,485

SEC source: 0001280776-17-000074 · wf-form4_149755850136766.xml · nonDerivative · entry 1

Winters Terence E. · CIK 0001591099 · Director · Co-Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,966

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-17-000072 · wf-form4_149747478861937.xml · nonDerivative · entry 1

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,942,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000073 · wf-form4_149755844275299.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,119

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.995 to $3.095. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4.

SEC source: 0001280776-17-000061 · wf-form4_149729794029409.xml · nonDerivative · entry 3

Satter Muneer A · CIK 0001315797 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,932,277

F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.975 to $3.20. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4.

F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.

SEC source: 0001280776-17-000066 · wf-form4_149739905118930.xml · derivative · entry 1

MURAWSKI RICHARD M · CIK 0001022850 · Vice President, Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2027-06-09

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-17-000070 · wf-form4_149739935757762.xml · derivative · entry 1

Winters Terence E. · CIK 0001591099 · Director · Co-Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-06-09

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-17-000069 · wf-form4_149739928897864.xml · derivative · entry 1

Swanson Michael V. · CIK 0001591694 · Chief Financial Officer, EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-06-09

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-17-000068 · wf-form4_149739922138803.xml · derivative · entry 1

Stern Aron · CIK 0001591106 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,143

Underlying: Common Stock · 22,143 shares

Expires 2027-06-09

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).

SEC source: 0001280776-17-000067 · wf-form4_149739911768796.xml · derivative · entry 1

Nash Duane · CIK 0001591098 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2027-06-09

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan).